ASC-话题@MedSci

#ASC#

1352篇内容 | 3971人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1939141, encodeId=2431193914182, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021: HIF-2α抑制剂Belzutifan在晚期肾透明细胞癌中初显疗效, objectType=article, longId=207202, objectId=75d220e20291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75d220e20291, replyNumber=0, likeNumber=0, createdTime=2021-11-02, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75d220e20291, moduleTitle=ASCO GU 2021: HIF-2α抑制剂Belzutifan在晚期肾透明细胞癌中初显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75d220e20291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939176, encodeId=3ae319391e607, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：摘要概览与展望11 |乳腺癌研究概览（浸润性乳腺癌专栏）, objectType=article, longId=211922, objectId=6faa2119225a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6faa2119225a, replyNumber=0, likeNumber=61, createdTime=2021-08-22, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6faa2119225a, moduleTitle=ASCO 2021：摘要概览与展望11 |乳腺癌研究概览（浸润性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6faa2119225a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939151, encodeId=31fe19391518f, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, objectType=article, longId=208095, objectId=2339208095d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2339208095d3, replyNumber=0, likeNumber=81, createdTime=2021-09-29, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2339208095d3, moduleTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2339208095d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939301, encodeId=10b21939301fa, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Journal Endovascular Therapy：DCB和BMS治疗股腘动脉病变，术后TLR发生率无差异？, objectType=article, longId=293597, objectId=44cf29359e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44cf29359e24, replyNumber=0, likeNumber=74, createdTime=2022-07-13, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44cf29359e24, moduleTitle=Journal Endovascular Therapy：DCB和BMS治疗股腘动脉病变，术后TLR发生率无差异？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44cf29359e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939133, encodeId=29f019391330c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021：前列腺癌的免疫治疗取得曙光, objectType=article, longId=207161, objectId=a18a20e161d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a18a20e161d3, replyNumber=0, likeNumber=84, createdTime=2021-07-01, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a18a20e161d3, moduleTitle=ASCO GU 2021：前列腺癌的免疫治疗取得曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a18a20e161d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939296, encodeId=8485193929634, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=《国家医保药品目录》落地：优化ASCVD患者的降脂方案，阿利西尤单抗直接医保应用, objectType=article, longId=293291, objectId=3ea9293291f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ea9293291f9, replyNumber=0, likeNumber=0, createdTime=2022-04-14, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ea9293291f9, moduleTitle=《国家医保药品目录》落地：优化ASCVD患者的降脂方案，阿利西尤单抗直接医保应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ea9293291f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939260, encodeId=04c1193926035, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：有DM的中度冠脉狭窄患者的预后比无DM的重度冠脉狭窄患者的预后更差！, objectType=article, longId=219321, objectId=0046219321fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0046219321fc, replyNumber=0, likeNumber=98, createdTime=2021-12-04, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0046219321fc, moduleTitle=Cardiovasc Diabetol：有DM的中度冠脉狭窄患者的预后比无DM的重度冠脉狭窄患者的预后更差！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0046219321fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939285, encodeId=48ce193928524, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Front Cardiovasc Med：HAS-BLED评分对AF患者出血风险的预测分析, objectType=article, longId=265042, objectId=520e2650423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=520e2650423e, replyNumber=0, likeNumber=70, createdTime=2022-06-29, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=520e2650423e, moduleTitle=Front Cardiovasc Med：HAS-BLED评分对AF患者出血风险的预测分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=520e2650423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939183, encodeId=b56e193918340, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021: 摘要概览与展望 17 | 肝细胞癌重磅研究进展（第二期）, objectType=article, longId=212157, objectId=195421215ead, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=195421215ead, replyNumber=0, likeNumber=59, createdTime=2021-08-05, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=195421215ead, moduleTitle=ASCO 2021: 摘要概览与展望 17 | 肝细胞癌重磅研究进展（第二期）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=195421215ead)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939283, encodeId=2701193928345, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：神奇，糖尿病患者低体重时的房颤风险很高，而超重时的房颤风险反而很低！, objectType=article, longId=221241, objectId=96d222124160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96d222124160, replyNumber=0, likeNumber=0, createdTime=2022-10-20, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96d222124160, moduleTitle=Cardiovasc Diabetol：神奇，糖尿病患者低体重时的房颤风险很高，而超重时的房颤风险反而很低！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96d222124160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939131, encodeId=56441939131d9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性, objectType=article, longId=205972, objectId=009f2059e2f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=009f2059e2f7, replyNumber=0, likeNumber=70, createdTime=2021-08-18, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=009f2059e2f7, moduleTitle=ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=009f2059e2f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939173, encodeId=802019391e3e7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案, objectType=article, longId=211898, objectId=a7cd21189859, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7cd21189859, replyNumber=0, likeNumber=71, createdTime=2021-10-30, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7cd21189859, moduleTitle=ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7cd21189859)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939261, encodeId=ef1e193926117, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=GW-ICC 2021：超高危ASCVD人群如何降血脂？我国新版规范3条核心要点必读！, objectType=article, longId=219490, objectId=82542194906e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82542194906e, replyNumber=0, likeNumber=105, createdTime=2022-07-26, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82542194906e, moduleTitle=GW-ICC 2021：超高危ASCVD人群如何降血脂？我国新版规范3条核心要点必读！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82542194906e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939239, encodeId=98071939239f5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：冠状动脉疾病患者的血清Nesfatin-1和DPP4水平及其相关性, objectType=article, longId=215782, objectId=053a215e8212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a215e8212, replyNumber=0, likeNumber=71, createdTime=2021-09-03, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a215e8212, moduleTitle=Cardiovasc Diabetol：冠状动脉疾病患者的血清Nesfatin-1和DPP4水平及其相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053a215e8212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939248, encodeId=b1271939248f1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=NeuroVasc 宣布中国首例 ENVI™-SR 机械取栓系统临床试验患者入组, objectType=article, longId=217595, objectId=632521e5954f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632521e5954f, replyNumber=0, likeNumber=62, createdTime=2021-10-06, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632521e5954f, moduleTitle=NeuroVasc 宣布中国首例 ENVI™-SR 机械取栓系统临床试验患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632521e5954f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Front Cardiovasc Med ：慢性阻塞性肺疾病患者的流感疫苗接种和室性心律失常风险：一项基于人群的纵向研究, objectType=article, longId=219876, objectId=349f2198e600, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=349f2198e600, replyNumber=0, likeNumber=94, createdTime=2022-04-18, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=349f2198e600, moduleTitle=Front Cardiovasc Med ：慢性阻塞性肺疾病患者的流感疫苗接种和室性心律失常风险：一项基于人群的纵向研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=349f2198e600)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939136, encodeId=f69b193913629, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021：上尿路尿路上皮癌的术后辅助化疗III期POUT试验结果更新, objectType=article, longId=207175, objectId=d83c20e175d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d83c20e175d0, replyNumber=0, likeNumber=68, createdTime=2021-09-25, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d83c20e175d0, moduleTitle=ASCO GU 2021：上尿路尿路上皮癌的术后辅助化疗III期POUT试验结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d83c20e175d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939229, encodeId=e26f1939229a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：甘油三酯-葡萄糖指数越高，动脉硬化风险越高！, objectType=article, longId=214529, objectId=0d0921452989, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d0921452989, replyNumber=0, likeNumber=59, createdTime=2021-11-20, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d0921452989, moduleTitle=Cardiovasc Diabetol：甘油三酯-葡萄糖指数越高，动脉硬化风险越高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d0921452989)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939180, encodeId=9be41939180ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021 ：摘要概览与展望14|非小细胞肺癌专题研究进展速递(02), objectType=article, longId=212102, objectId=0a5521210244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a5521210244, replyNumber=0, likeNumber=88, createdTime=2021-08-28, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a5521210244, moduleTitle=ASCO 2021 ：摘要概览与展望14|非小细胞肺癌专题研究进展速递(02), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a5521210244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939234, encodeId=7a3c193923442, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Arterioscler Thromb Vasc Biol：青春期超重/肥胖或增加中年急性冠状动脉发生风险, objectType=article, longId=214982, objectId=8496214982ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8496214982ec, replyNumber=0, likeNumber=64, createdTime=2021-12-29, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8496214982ec, moduleTitle=Arterioscler Thromb Vasc Biol：青春期超重/肥胖或增加中年急性冠状动脉发生风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8496214982ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASC

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021: HIF-2α抑制剂Belzutifan在晚期肾透明细胞癌中初显疗效

2021-11-02

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：摘要概览与展望11 |乳腺癌研究概览（浸润性乳腺癌专栏）

2021-08-22

quxin068 (审核中...)

前往app查看评论内容

#ASC#

“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI

2021-09-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Journal Endovascular Therapy：DCB和BMS治疗股腘动脉病变，术后TLR发生率无差异？

2022-07-13

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021：前列腺癌的免疫治疗取得曙光

2021-07-01

quxin068 (审核中...)

前往app查看评论内容

#ASC#

《国家医保药品目录》落地：优化ASCVD患者的降脂方案，阿利西尤单抗直接医保应用

2022-04-14

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：有DM的中度冠脉狭窄患者的预后比无DM的重度冠脉狭窄患者的预后更差！

2021-12-04

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Front Cardiovasc Med：HAS-BLED评分对AF患者出血风险的预测分析

2022-06-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021: 摘要概览与展望 17 | 肝细胞癌重磅研究进展（第二期）

2021-08-05

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：神奇，糖尿病患者低体重时的房颤风险很高，而超重时的房颤风险反而很低！

2022-10-20

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性

2021-08-18

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案

2021-10-30

quxin068 (审核中...)

前往app查看评论内容

#ASC#

GW-ICC 2021：超高危ASCVD人群如何降血脂？我国新版规范3条核心要点必读！

2022-07-26

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：冠状动脉疾病患者的血清Nesfatin-1和DPP4水平及其相关性

2021-09-03

quxin068 (审核中...)

前往app查看评论内容

#ASC#

NeuroVasc 宣布中国首例 ENVI™-SR 机械取栓系统临床试验患者入组

2021-10-06

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Front Cardiovasc Med ：慢性阻塞性肺疾病患者的流感疫苗接种和室性心律失常风险：一项基于人群的纵向研究

2022-04-18

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021：上尿路尿路上皮癌的术后辅助化疗III期POUT试验结果更新

2021-09-25

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：甘油三酯-葡萄糖指数越高，动脉硬化风险越高！

2021-11-20

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021 ：摘要概览与展望14|非小细胞肺癌专题研究进展速递(02)

2021-08-28

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Arterioscler Thromb Vasc Biol：青春期超重/肥胖或增加中年急性冠状动脉发生风险

2021-12-29

科室
- - 订阅+
  - 更多科室
工具
服务